GlassScriptPhysician profile
Sang U Kim
NPI 1225070170
$10,911.72
in general payments reported to CMS, 2019-2025
29 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,437 · 2020: $165 · 2021: $112 · 2022: $686 · 2023: $1,272 · 2024: $1,296 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,845.38 | 2019-2025 | |
| Abbvie INC. | $1,375.46 | 2019-2025 | |
| Pfizer INC. | $720.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $545.54 | 2019-2025 | Entyvio, Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.70 | 2019-2024 | Trulance |
| Phathom Pharmaceuticals, INC. | $301.99 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $276.32 | 2022-2023 | Rebyota |
| Janssen Biotech, INC. | $269.41 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $189.01 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $140.73 | 2022-2024 | Dupixent |
| Aries Pharmaceuticals, INC. | $108.42 | 2019 | |
| Allergan, INC. | $86.07 | 2019 | |
| Qol Medical, LLC | $75.46 | 2023-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $73.69 | 2019-2023 | Dificid |
| Aimmune Therapeutics, INC. | $71.46 | 2025 | Vowst, Zenpep |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $61.73 | 2022 | |
| Organon LLC | $61.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $58.95 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $54.68 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $52.69 | 2022-2024 | Zeposia |
| Shire North American Group INC | $33.87 | 2019 | |
| Lilly USA, LLC | $27.61 | 2024 | Omvoh |
| Ardelyx, INC. | $26.91 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $23.72 | 2020 | |
| Ucb, INC. | $23.42 | 2019 | |
| Celltrion USA INC. | $23.27 | 2024 | Vegzelma |
| Braintree Laboratories, INC. | $22.65 | 2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $13.09 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,800.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sang Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.